PRX 08066

Drug Profile

PRX 08066

Alternative Names: PRX-08066; PRX-8066

Latest Information Update: 30 Apr 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EPIX Pharmaceuticals
  • Developer Clinical Data
  • Class Antihypertensives; Pyrimidines; Small molecules; Thiophenes
  • Mechanism of Action Serotonin 2B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary hypertension

Highest Development Phases

  • No development reported Pulmonary arterial hypertension

Most Recent Events

  • 30 Apr 2012 No development reported - Phase-II for Pulmonary hypertension in USA (PO)
  • 13 Apr 2011 Clinical Data has been acquired by Forest Laboratories
  • 02 Nov 2010 PRX 08066 receives Orphan Drug status for Pulmonary arterial hypertension in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top